Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Sienna Biopharmaceuticals
company
About
Clinical development and commercialization of innovative aesthetics and medical dermatology products based on scientific breakthroughs
- 11 - 50
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $12M
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 2010
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$86M
Sienna Biopharmaceuticals has raised a total of
$86M
in funding over 2 rounds. Their latest funding was raised on
Apr 24, 2017 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 24, 2017 | Series B | $40M | 1 |
ARCH Venture Partners
|
— | Detail |
| Jul 12, 2016 | Series A | $12M | 1 |
ARCH Venture Partners
|
— | Detail |
| Apr 28, 2016 | Series A | $34M | 1 |
ARCH Venture Partners
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
3
1
Sienna Biopharmaceuticals is funded by 1 investors.
ARCH Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
Yes | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
